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occurred during concomitant EBRT-CT and resolved after a 
week of medical therapy. At 12 months from the end of 
treatment, response rate was 87.5% (35/40); we recorded 4 
persistent disease and 1 locoregional recurrence (after 6 
months), occurred in all patients with stage III. After 12 
months of follow-up,we reported disease progression (1 
central and 1 systemic) in 2 patients (5%), respectively at 17 
and 48 months from the end of radiation therapy. Patient 
showing central relapse underwent radical hysterectomy and 
patient with systemic disease started chemotherapy.  
 
Conclusion: In our experience, the association of 
concomitant EBRT-CT and HDR-BRT(Fletcher applicator) 
represents a well tolerated treatment for patients with 
advanced cervical cancer, with good results in terms of acute 
and late toxicity and local control 
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Purpose or Objective: To investigate the need for the 
implementation and development of immobilization and 
localization devices and other improvements in safety 
measures in addition to those currently in use in current HDR 
treatment protocols involving gynecological applicators.  
 
Material and Methods: 55 treatment plans from 27 cervical 
cancer patients treated with three to 5 intra-cavity cylinder 
insertions were used. We performed a retrospective study of 
a dosimetric evaluation due to a possible minor displacement 
of the cylinder after scanning to the treatment delivery time. 
The 55 plans that were dosimetrically analyzed post 
treatment involved treatments for 27 different patients. 22 
patients had a hysterectomy with bilateral salpingo-
oophorectomy . In 16 of these twenty two patients the 
procedure had an abdominal hysterectomy bilateral salpingo-
oophorectomy).Three of the patients had hysterectomies 
only. The vaginal cylinder applicators which were placed 
within the patients by a radiation oncologist for 
administering the treatments included the Capri, Miami, and 
multi-lumen catheres applicator. 
 
Results: For the 55 patients whose point dose data were 
gathered, dose variation at the hottest spot due to a 
simulated 1mm displacement in the superior inferior 
direction calculated by normalizing to the average of the 
endpoints was found to have a minimum value of 0.02% and a 
maximum value of 12.66% with an average value of 1.43% and 
a standard deviation of 2.02%. Dose variation at the hottest 
spot due to a simulated 1mm displacement in the medial 
lateral direction calculated by normalizing to the average of 
the endpoints was found to have a minimum value of 12.32% 
and a maximum value of 22.71% with an average value of 
16.96% and a standard deviation of 2.76%. The measurement 
of dose variation due to a displacement of one degree of 
rotation along the central axis of the applicator was found to 
have a minimum value of 0.00% and a maximum value of 
2.76% with an average value of 0.63% and a standard 
deviation of 0.62%.The standard deviation and the mean 
nearly coincide. The measurement of dose variation due to a 
displacement of five degrees of rotation along the central 
axis of the applicator was found to have a minimum value of 
0.06% and a maximum value of 13.71% with an average value 
of 2.15% and a standard deviation of 3.00%. 
 
Conclusion: The point dose variation due to hypothetical 1 
mm medial lateral displacement of a vaginal cylinder 
applicator make a difference in terms of Grade 1 rectal 
toxicity as defined by Common Terminology Criteria for 
Adverse Events v 4.0 in some patients receiving HDR VCBT 
alone or shortly after EBRT. The point dose variation due to 
hypothetical 1 mm medial lateral displacement of a vaginal 
cylinder applicator according to this analysis did reach a 
crudely obtained cutoff value for RTOG grade greater than or 
equal to 2 late rectal morbidity for any of the patients 
receiving HDR VCBT alone or shortly after EBRT. 
 
EP-1978  
Individualized approach to brachytherapy in cervical 
cancer patient: a case report study. 
B.H. Zobec Logar
1Institute of Oncology Ljubljana, Radiotherapy, Ljubljana, 
Slovenia 
1, R. Hudej1 
 
Purpose or Objective: In some cervical cancer patients with 
extensive parametrial involvement, not all of the tumor can 
be sufficiently covered with MRI-based image guided 
brachytherapy using a standard intracavitary/interstitial 
applicator. An approach with individually designed applicator 
with oblique needles offers a possibility of better tumor dose 
coverage in these patients.In this study we tested the 
feasibility of the 3D printing for the individualized 
brachytherapy applicator add-on. 
 
Material and Methods: A patient in this case report study had 
extensive parametrial involvement to the pelvic wall. In 
order to improve the tumor dose coverage we decided to use 
additional oblique needles for the second application. A 
preplan for the second application was created based on the 
dosimetry information from the first application. The 
information on the optimal location of the oblique needles in 
the preplan was used to design an individualized interstitial 
template cap for the ring applicator, which was 
manufactured with a 3D printing technique. The whole 
procedure of the cap design and manufacture was performed 
in 5 days. 
 
Results: The HR-CTV coverage at the time of the first 
application (Figure 1a) was suboptimal (D90=69%, D100=35%, 
V100=77%).  
 
 
